Biotech Movers

Biotech Movers: Affymax Crashes on Recall

Last week, shares of Affymax got hammered when the company pulled back units of its sole commercial drug. Plus, find out what sent the biggest gainers skyward. More 

Biotech Movers: Chelsea Doubles, Vivus Dips

Last week, Vivus slipped on a rejection from European regulators. Plus, find out why Chelsea Therapeutics and Infinity Pharmaceuticals soared. More 

Biotech Movers: Big Bumps All Around

Last week, big names from Ziopharm Oncology to StemCells posted stellar gains, while Amicus Therapeutics shaked the positive trend with a hearty tumble. More 

Biotech Movers: A Doubler for Opexa

A good week for little guys Opexa Therapeutics and Hyperion Therapeutics and giant Biogen. But Hemispherx BioPharma and BioCryst Pharmaceuticals had downers. More 

Biotech Movers: Keryx Jumps, Sarepta Slips

Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades. More 

Biotech Movers: Dendreon Pops, ArQule Drops

An analyst upgrade on DNDN lifted the shares 21% last Friday, but mid-stage trial failure of a colorectal drug sank ARQL 11% the same day. More 

Biotech Movers: Ariad Sinks, YM Soars

They were among the sector's big newsmakers last week, with Acadia, Oncolytics and Acura Pharmaceuticals. More 

Biotech Movers: A Tough Week All Around

Amarin Corp. slides on dashed buyout hopes, while Sarepta, Galena and others also faced serious setbacks. More 

Biotech Movers: Acadia Rockets on Trial News

Acadia Pharmaceuticals leads the way with a week of eye-popping gains. Plus: Why Exelixis and Supernus took tough tumbles. More 

Biotech Movers: Regeneron Pops, 3 Flop

While Regeneron soared on behind its macular degeneration treatment, Dynavax, Navidea and AspenBio suffered serious setbacks. More